Table of Contents
ISRN Ophthalmology
Volume 2013 (2013), Article ID 464218, 8 pages
http://dx.doi.org/10.1155/2013/464218
Clinical Study

Ocular Risk Factors for Exudative AMD: A Novel Semiautomated Grading System

1Centro Hospitalar e Universitário de Coimbra (CHUC), 3000-075 Coimbra, Portugal
2Association for Innovation and Biomedical Research on Light and Image (AIBILI), 3000-548 Coimbra, Portugal
3Critical Health SA, 3045-504 Coimbra, Portugal
4Faculty of Medicine, 3004-504 Coimbra, Portugal

Received 2 May 2013; Accepted 29 May 2013

Academic Editors: A. M. Avunduk and B. V. Bui

Copyright © 2013 João Pedro Marques et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To evaluate the contribution of the ocular risk factors in the conversion of the fellow eye of patients with unilateral exudative AMD, using a novel semiautomated grading system. Materials and Methods. Single-center, retrospective study including 89 consecutive patients with unilateral exudative AMD and ≥3 years of followup. Baseline color fundus photographs were graded using an innovative grading software, RetmarkerAMD (Critical Health SA). Results. The follow-up period was months. The occurrence of CNV was confirmed in 42 eyes (47.2%). The cumulative incidence of CNV was 23.6% at 2 years, 33.7% at 3 years, 39.3% at 5 years, and 47.2% at 10 years, with a mean annual incidence of 12.0% (95%  0.088–0.162). The absolute number of drusen in the central 1000 and 3000 μm ( ) and the absolute number of drusen ≥125 µm in the central 3000 and 6000 µm ( ) proved to be significant risk factors for CNV. Conclusion. The use of quantitative variables in the determination of the OR of developing CNV allowed the establishment of significant risk factors for neovascularization. The long follow-up period and the innovative methodology reinforce the value of our results. This trial is registered with ClinicalTrials.gov NCT00801541.